New approaches to tumor therapy with siRNA-decorated and chitosan-modified PLGA nanoparticles

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapeutics

Background:

• Metastatic cancers often cause significant pain, necessitating treatments that manage symptoms alongside tumor control.
• Current cancer therapies may not adequately address symptom alleviation, particularly pain.
• A dual-action therapeutic strategy targeting both cancer cell death and pain relief is highly desirable.

Purpose of the Study:

• To develop a modified polymeric nanoparticle (NP) system for inducing cancer cell apoptosis.
• To incorporate pain management capabilities into the NP system.
• To create a novel therapeutic approach for metastatic cancers and associated pain.

Main Methods:

• Chitosan-modified poly(lactic-co-glycolic acid) (PLGA) NPs were synthesized via nanoprecipitation.
• NPs were loaded with flurbiprofen (pain reliever) and decorated with folic acid for targeted delivery.
• STAT3-siRNA was adsorbed onto the NPs using antisense technology to induce apoptosis.

Main Results:

• The developed NPs exhibited optimal size (176.9–220.3 nm) and positive zeta potential (+14.1 to +27.2 mV).
• High drug loading capacity and sustained release of flurbiprofen over 144 hours were observed.
• Folic acid facilitated cancer cell uptake, and siRNA demonstrated effective electrostatic interaction, leading to enhanced cytotoxicity.

Conclusions:

• The developed formulation serves as a promising dual-action carrier system for cancer treatment and pain prevention.
• This approach is particularly relevant for managing metastatic cancers and their associated symptoms.
• The study highlights the potential of targeted nanoparticles in simultaneously addressing tumor progression and patient discomfort.